The investment round was led by Forbion Capital Partners.
The funding will be used to advance the company’s lead product, EG-12, into clinical trials. EG-12 is a carrier-DNA complex designed for the treatment of ulcerative colitis. The product aims to produce intestinal-localized expression of anti-inflammatory cytokine IL-10, according to the report.
“The unique technology of enGene effectively turns the gut into a protein factory, and given the strong genetic relation between IL-10 and ulcerative colitis, we expect EG-12 to provide significant benefit to IBD patients,” said Forbion managed partner Sander van Deventer, MD, PhD.
More articles on gastroenterology:
What do GI fellows need to know before establishing a practice?
AGA addresses duodenoscope infection risks
Bill requiring payers to cover CRC screening introduced in Kentucky
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.